Printed from https://ideas.repec.org/s/adp/oamabb.html
Content
March 2017, Volume 1, Issue 1
- 1-2 Can we Reduce the Cost of Treatment of Acute Pneumonia?
by Igor Klepikov
My serials
Follow this serial
Juniper Publishers Inc.
Modern Applications of Bioequivalence & Bioavailability
Contact information of Juniper Publishers Inc.
Serial Information
Editor: Sophia Mathis
Description: Modern Applications of Bioequivalence & Bioavailability is committed to publish original research in all aspects of areas of Bioequivalence and Bioavailability through rapid peer-review process. MABB aims to promote more information about Bioequivalence and Bioavailability and its related science to enhance the exchange of scientific knowledge among peers. Juniper strongly welcomes researchers for submission of papers in different formats like original research papers, review articles, News, short communications, Opinions, letter to editors on a breadth of topics related to Regulatory Requirements in Bioequivalence, Biosimilars, Advances in Bioavailability, FDA Bioequivalence, Absolute bioavailability, Biowaivers, Clinical pharmacy, Toxicology, Biosimilars, Bioaccessibility, and other interesting topics related to Bioequivalence and Bioavailability.
Series handle: RePEc:adp:oamabb
Citations RSS feed: at CitEc
Impact factors
- Simple (last 10 years)
- Recursive (10)
- Discounted (10)
- Recursive discounted (10)
- H-Index (10)
- Euclid (10)
- Aggregate (10)
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:oamabb. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .